Cytology-based gene mutation tests to predict response to anti-epidermal growth factor receptor therapy: a review

Area of Science:

• Oncology
• Molecular Diagnostics
• Cancer Genetics

Background:

• Targeted therapies for nonsmall cell lung cancer (NSCLC) and colorectal cancer (CRC) rely on specific genetic mutations.
• Epidermal growth factor receptor (EGFR) inhibitors are key treatments, necessitating predictive biomarker testing.
• Cytological samples offer a less invasive alternative to surgical biopsies for molecular testing.

Purpose of the Study:

• To review studies utilizing gene mutation assays on cytological samples for NSCLC and CRC.
• To evaluate the role of cytological samples in patient selection for anti-EGFR therapy.
• To emphasize the importance of cytopathologist expertise in ensuring diagnostic quality.

Main Methods:

• Literature review of studies investigating gene mutation testing on cytological specimens.
• Analysis of EGFR and KRAS mutation detection in NSCLC and CRC, respectively.
• Assessment of factors influencing the reliability of molecular testing in cytology.

Main Results:

• Gene mutation testing on cytological samples is feasible and effective for guiding anti-EGFR therapy in NSCLC and CRC.
• Successful identification of EGFR mutations in NSCLC and KRAS mutations in CRC from cytology specimens.
• The quality and accuracy of mutation test results are significantly influenced by the cytopathologist's role.

Conclusions:

• Cytological samples are a valuable resource for molecular diagnostics in NSCLC and CRC patient management.
• Accurate gene mutation testing on cytology specimens is critical for the successful application of targeted therapies.
• Enhanced collaboration between pathologists and oncologists is essential for optimizing patient selection and treatment outcomes.